AbCellera FY2023 revenue $38M (down 92% YoY), net loss $0.51/share

AbCellera Biologics Inc.

2023-FY EPS reported -$0.51 revenue$38,025,000

Revenue fell to $38.0M from $485.4M in FY2022; research fees were $35.6M.
Net loss of $146.4M ($0.51 basic & diluted EPS) vs net income of $158.5M in 2022.
R&D expenses surged to $175.7M (up 63% YoY) on program and platform investments.
Cumulative partner-initiated program starts reached 87; 13 molecules in clinic.
Advanced two internal programs (ABCL635, ABCL575) into IND-enabling studies.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbCellera Biologics Inc. reported full year 2023 results: revenue $38.0 million, net income $146.4 million, or $(0.51) per share on a basic and diluted basis, EPS $(0.51) per share on a basic and diluted basis.

Period: full year 2023
Revenue: $38.0 million
Net income: $146.4 million, or $(0.51) per share on a basic and diluted basis
EPS: $(0.51) per share on a basic and diluted basis
Result: reported results

Exact text from the filing

the press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- NEWS RELEASE AbCellera Reports Full Year 2023 Business Results 2/20/2024 ● Total revenue of $38 million, compared to $485 million in FY 2022 ● Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the year ● Net loss of $0.51 per share on a

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-24-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.